stockportfolio.pro
Erasca, Inc. (ERAS)
Healthcare · Biotechnology · NasdaqGS
Erasca, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-101.66M | $-122.76M | $-242.81M | $-125.04M | $-161.65M | $-124.55M |
| Net margin | — | — | — | — | — | — |
Source: Erasca, Inc. SEC filings (10-K).
Explore 6 years of Erasca, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ERAS in your portfolio →
Erasca, Inc. financial history by metric
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc. — frequently asked questions
What is Erasca, Inc.'s revenue?
Erasca, Inc. (ERAS) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Erasca, Inc. profitable?
No — ERAS reported a net loss of $-124.55M in fiscal 2025.
What is ERAS's P/E ratio?
Erasca, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Erasca, Inc. have?
As of fiscal year 2025, ERAS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Erasca, Inc.'s market cap?
Erasca, Inc. (ERAS) has a market capitalization of about $4.24B, based on the latest data in our nightly-refreshed cache.
When does Erasca, Inc.'s fiscal year end?
ERAS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Erasca, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.